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Inclusion criteria 
Studies:  
Randomized controlled trials. 
Participants: 
People with a diagnosed depressive disorder, 
including major depressive disorder, dysthymic 
disorder, and bipolar affective disorder. 
Intervention: 
Inositol compared with placebo; inositol compared 
with antidepressant medication; inositol plus 
antidepressant compared with antidepressant alone. 
Outcomes: 
Resolution of depressive symptoms (primary); drop-out 
rates; adverse events; quality of life; clinical 
impression; relapse or onset of manic episode; social 
and occupational functioning; hospital admissions; 
death from any cause, suicide or undetermined injury.  
Results 
• Four trials with a total of 142 participants were 
included; all were randomized but allocation 
concealment was unknown. 
• There were no significant differences in resolution 
of depressive symptoms  (assessed using the 
Hamilton Depression Rating Scale) between people 
taking inositol and those taking glucose placebo, 
either alone or with antidepressants, (standardized 
mean score difference -0.08, 95% confidence 
interval (CI) -0.45 to 0.30;113 participants, 4 trials).  
• There were no significant differences between 
inositol and placebo in drop-out rates (relative risk 
1.49, 95% CI 0.77 to 2.90; 142 participants, 4 
trials), or adverse events (relative risk 0.89, 95% CI 
0.48 to 1.64 ; 142 participants, 4 trials).  
• There were no trials assessing other outcomes. 
Can inositol be used to treat depression? 
There is insufficient evidence of the effectiveness and safety of  
inositol for treating depressive disorders. 
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Authors’ conclusions 
Implications for practice:  
There is insufficient evidence of the efficacy and safety of inositol for treating depressive disorders, either alone 
or in combination with antidepressant therapy.  
Implications for research: 
Large, well-designed trials examining the effectiveness of inositol for treating depressive disorders are needed. 
Trials should report more comprehensively on outcomes including death, quality of life and treatment 
acceptability. 
The Cochrane Database of Systematic Reviews is available from www.wiley.com, and free for eligible countries through www.healthinternetwork.org.  
Inositol versus glucose (placebo): depressive symptom score (Hamilton Scale) at four to six weeks  
